[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"charcot-marie-tooth-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:charcot-marie-tooth-disease":146},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,51,81,106,134,163,195,216,285],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100595883","genotypephenotype-correlation-of-morc2-mutations-100595883",false,"NCT07038239","Genotype\u002FPhenotype Correlation of MORC2 Mutations","Deciphering MORC2 Genotype\u002FPhenotype Correlation to Improve Patient Diagnostic","PhenoMORC2","Inclusion Criteria:\n\n* Presence of a mutation in the MORC2 gene, identified during an evaluation for peripheral neuropathy or intellectual disability\n* Patient has undergone electromyography (EMG) or is able to undergo EMG during the inclusion visit\n* Affiliation with the national health insurance system\n* Informed consent from the patient if an adult, or from parents\u002Flegal guardians if the patient is a minor\n\nExclusion Criteria:\n\n* Presence of another mutation responsible for peripheral neuropathy or intellectual disability\n* Refusal to undergo biological sample collection\n* Regulatory exclusion criteria:\n* Pregnant, postpartum, or breastfeeding women\n* Individuals deprived of liberty by judicial or administrative decision\n* Individuals not affiliated with a social security system or not benefiting from an equivalent health coverage scheme","ALL","4 Years",{"count":20,"type":21},45,"ESTIMATED","OBSERVATIONAL","The Microrchidia CW-type zinc finger 2 (MORC2) gene encodes a protein expressed in all tissues and enriched in the brain. It is involved in Charcot-Marie-Tooth disease, with mire than 30 families presenting MORC2 mutations. Recently, MORC2 mutation have been shown to be responsible for more complex phenotypes like DIFGAN: developmental delay, impaired growth, dysmorphic facies and axonal neuropathy.\n\nDifferent mutations are responsible from a diverse spectrum of phenotype, from CMT to DIFGAN.\n\nMORC2 is involved, through its ATPase activity, in DNA repair, chromatin remodeling and epigenetic silencing via the Human silencing hub (HUSH) complex. Our hypothesis is that the hypo- or hyper-activation of the HUSH complex by different MORC2 mutations could be responsible for different phenotypes in patients. The aim of this study is to perform a genotype-phenotype correlation study in patients presenting MORC2 mutations.",[25,26,27,28,29],"Charcot Marie Tooth Disease","DIFGAN","Developmental Delay (Disorder)","Impaired Growth","Dysmorphic Facies and Axonal Neuropathy",[31,26,32,33,34,35,36,37],"Charcot-Marie-Tooth","Human silencing hub complex","genotype-phenotype correlation","MORC2","DNA dalage repair","transcriptional modulation","EPIGENETIC","RECRUITING","2026-06-17",{"date":41,"type":42},"2026-06-18","ACTUAL",{"date":44,"type":42},"2026-06-16",{"date":46,"type":21},"2027-06",{"name":48,"class":49},"Hospices Civils de Lyon","OTHER",12,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":17,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100636805","tremor-in-charcot-marie-tooth-100636805","NCT07570459","TREMOR IN CHARCOT-MARIE-TOOTH","Investigation of Tremor in Patients With Charcot-Marie-Tooth Neuropathy","CMT-TREM","Inclusion Criteria:\n\n* Clinical CMT Diagnosis \u002F Anamnestically Healthy Control Group\n* Genetic confirmation of CMT in adult patients\n* Ability to achieve the outcome measure at baseline\n* Age between 18 and 65 years\n* Capacity of all study participants to consent and signed informed consent, including patient or participant information and consent form\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding period\n* Other relevant neurological or psychiatric disorders, acute or in the past history\n* Presence of a serious previous internal disease",true,"18 Years","65 Years",{"count":63,"type":21},75,"Tremor is a symptom that has already been described in many case reports and case series concerning patients with Charcot-Marie-Tooth (CMT) disease. However, the pathophysiology of tremor in this condition remains largely unclear. It has also not been sufficiently investigated to what extent tremor in CMT patients constitutes a relevant impairment of quality of life.\n\nThis project focuses on a more detailed characterization of tremor in CMT patients using surface electromyography and accelerometer analysis, as well as the collection of individual clinical data, particularly regarding the symptom of tremor, in order to facilitate the characterization and etiological classification of the tremor. In addition, a questionnaire-based assessment will be conducted to capture the impact of tremor on activities of daily living and the associated burden in this specific patient cohort.\n\nThe entire data collection process will be supported by a clinical examination, which will be video-recorded by experienced neurologists to ensure more reliable analysis. This serves both the characterization of tremor and the illustration of its functional limitations. Where available, the data will be correlated with genetic variants to allow conclusions about possible genetic predispositions or disease progression. As a control group, CMT patients who have not yet reported a tremor will be included.",[66,67,68,25],"CMT","CMT (Charcot Marie Tooth Disease)","Charcot Marie Tooth Disease (CMT)",[70],"Tremor in CMT","2026-04-29",{"date":73,"type":42},"2026-05-06",{"date":75,"type":42},"2024-07-30",{"date":77,"type":21},"2026-10-30",{"name":79,"class":49},"University Medical Center Goettingen",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":59,"sex":17,"minAge":60,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100567332","observational-study-to-observe-variations-of-gait-parameters-in-patients-with-neuromuscular-diseases-100567332","NCT06666816","Observational Study to Observe Variations of Gait Parameters in Patients With Neuromuscular Diseases","Observational Study for the Identification of Fatigue and Gait Biomarkers in Populations With Neuromuscular Pathologies in the Clinical Context and Daily Life","Inclusion Criteria:\n\n* Ambulant adult patients with genetic diagnosis of muscular dystrophy\u002Fmyopathy (dystrophinopathies, muscular dystrophies and congenital and non-congenital myopathies), of spinal muscular atrophy (SMA) and with molecular diagnosis of Charcot-Marie Tooth 1 or 2.\n* independent walking, even with assistance;\n\nExclusion Criteria:\n\n* Dilated or ischemic heart disease with moderate impairment;\n* Chronic respiratory failure: forced vital capacity (FVC) \\\u003C 40%; more than 5% of nocturnal time spent with peripheral oxygen saturation levels \\\u003C 90.","75 Years",{"count":90,"type":21},120,"This study has the general objective of observing walking parameters during a clinical test to objectively estimate fatigue in patients with neuromuscular diseases. Furthermore, the investigators want to evaluate the feasibility of collecting physical activity in daily life conditions during a one-week monitoring period using a wearable sensor.",[93,94,95,25],"Muscular Dystrophies","Myopathies","Spinal Muscular Atrophy (SMA)","2026-01-15",{"date":98,"type":42},"2026-01-20",{"date":100,"type":42},"2017-10-27",{"date":102,"type":21},"2026-12",{"name":104,"class":49},"IRCCS Eugenio Medea",2,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":59,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":131,"locationsCount":133},"100147629","natural-history-evaluation-of-charcot-marie-tooth-disease-cmt-types-cmt1b-cmt2a-cmt4a-cmt4c-and-others-100147629","NCT01193075","Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others","Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Type (CMT1B), 2A (CMT2A), 4A (CMT4A), 4C (CMT4C), and Others","INC-6601","Inclusion Criteria:\n\nAll patients must be seen in-person at a participating center for the initial visit.\n\nInclusion Criteria - patients with CMT (all subtypes)\n\n1. Patient has documented, pathogenic or likely pathogenic CMT-causing variant(s)\n\n   OR\n2. Patient has a first- or second-degree family member (parent, child, sibling, half-sibling, aunt, uncle, grandparent, or grandchild) with a documented pathogenic or likely pathogenic CMT-causing variant AND a clear link between that family member and the affected patient AND a phenotype consistent with the diagnosis\n\n   i. A clear link is necessary for a second-degree relative. For example, if a grandparent is affected and has a pathogenic or likely pathogenic variant, and the parent does not have any signs, symptoms, or electrophysiology consistent with the diagnosis, there is no clear link unless the parent has also been found to have the pathogenic or likely pathogenic variant such as in cases with reduced penetrance\n\n   ii. In cases where clear links are not available, genetic testing is required for the patient or the family member who is not clearly affected.\n3. Patients who have a variant of uncertain significance, as determined by the laboratory performing the testing may still be included if one of the following circumstances applies:\n\n   i. Variant is categorized as pathogenic or likely pathogenic per the ACMG variant interpretation guidelines. \\[80, 81\\]\n\n   ii. Variant has been found in multiple affected people in a family and has not been found in unaffected family members. (Note - both affected and unaffected family members must be tested in this situation to be included).\n\n   iii. The principal investigator and the site investigator agree that the variant(s) is (are) most likely pathogenic.\n4. Patients whose clinical presentation is suggestive of CMT, but CMT type and variant are unknown will be characterized by the following categories:\n\n   1. Nerve conduction velocities: demyelinating, axonal, intermediate\n   2. Inheritance: dominant, recessive, X-linked, or unknown\n5. Patient or patient's legally authorized representative has understood and signed an IRB approved consent form for the study. Teenagers (age 13 - 17 years) and cognitively impaired adults who are able to read and write must sign an assent form (depending on local ethics committee requirements).\n\nInclusion Criteria - Controls\n\n1. Person does not have a peripheral neuropathy, as determined by the investigator.\n2. Person has understood and signed an IRB approved consent form for the study. Teenagers (age 13-17 years) must sign an assent form (depending on local ethics committee requirements).\n\nEXCLUSION CRITERIA\n\n1. Patient has a variant of uncertain significance that cannot be further classified following methods listed in the Inclusion Criteria.\n2. Patient does not wish to be a part of the study or has not signed an informed consent form.\n3. Patient is deemed inappropriate by the Site PI.",{"count":115,"type":21},5000,"This is an observational longitudinal study to determine the natural history and genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C).\n\nThe investigators will also be determine the capability of the newly developed CMT Pediatric Scale (CMT Peds scale) and the Minimal Dataset to measure impairment and perform longitudinal measurements in patients with multiple forms of CMT over a five year window",[25],[119,66,120,121,122,123,124],"Charcot Marie Tooth disease","HMSN","HMN","HSN","CMT1","CMT2","2025-10-01",{"date":127,"type":42},"2025-10-07",{"date":129,"type":42},"2010-04-01",{"date":102,"type":21},{"name":132,"class":49},"Michael Shy",22,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":144,"conditions":145,"keywords":149,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":80},"100440108","nt-3-levels-and-function-in-individuals-with-cmt-100440108","NCT05011006","NT-3 Levels and Function in Individuals With CMT","Correlation of Circulating NT-3 Levels and Function in Individuals With Peripheral Neuropathy or Charcot-Marie-Tooth Neuropathy","Inclusion Criteria:\n\n* Males or females from 7 years of age or older\n* Diagnosis of acquired peripheral neuropathy (PN) such as due to diabetes, chemo-induced, autoimmune chronic inflammatory demyelinating polyneuropathy (CIDP) established by a report of electrical studies or with a known genetic CMT diagnosis. Definitive diagnosis of PN is established with a report of electrical studies, EMG\u002Fnerve conduction studies.2\n* Perform assessments to the best of their ability with reliable results as deemed by the evaluator.\n* Ability to attend scheduled appointments\n* Ability to provide informed consent (or assent for ages 9-18)\n\nExclusion Criteria:\n\n* Current pregnancy per medical history\n* Has a medical condition or extenuating circumstances that, in the opinion of the investigator, might compromise the subject's wellbeing, safety, or clinical interpretability","7 Years",{"count":143,"type":21},50,"This study will assess the serum NT-3 levels in individuals with the diagnosis of peripheral neuropathy or any type of Charcot-Marie-Tooth Neuropathy (CMT) and correlate this with function.",[146,147,148],"Charcot-Marie-Tooth Disease","Peripheral Neuropathy","Chronic Inflammatory Demyelinating Polyneuropathy",[150,151,152],"NT-3","CMT1A","Neuropathy","NOT_YET_RECRUITING","2025-06-18",{"date":156,"type":42},"2025-06-24",{"date":158,"type":21},"2027-11-13",{"date":160,"type":21},"2030-06",{"name":162,"class":49},"Zarife Sahenk",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":174,"phases":175,"briefSummary":177,"conditions":178,"keywords":181,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":194},"100583872","high-tech-rehabilitation-pathway-for-chronic-adult-neuromuscular-diseases---fit4medrob-chronic-mnd-project-100583872","NCT06881979","High-Tech Rehabilitation Pathway for Chronic Adult Neuromuscular Diseases - Fit4MedRob-Chronic MND Project","Clinical Protocol for a Pragmatic Trial on a High-Tech Rehabilitation Pathway for Chronic Adult Neuromuscular Diseases (Fit4MedRob-Chronic MND Project)","Fit4MR-ChrMND","Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of chronic neuromuscular diseases (e.g. ALS, CIDP, CMT)\n* Patient able to walk independently or with assistance\n* Patients capable of understanding and adhering to the study protocol.\n* Patients who have provided informed consent to participate in the study\n\nExclusion Criteria:\n\n* Patients with unstable medical conditions (e.g. severe cardiovascular diseases, such as \"New York Heart Association\" - NYHA=4, respiratory distress not compensated by ventilation) that could interfere, in the clinician's judgment, with their ability to safely participate in the study or to perform the assessments related to the protocol.\n* Patients currently participating in other clinical trials that could interfere with this study.\n* Pregnant women.","80 Years",{"count":173,"type":21},60,"INTERVENTIONAL",[176],"NA","The primary objective is to demonstrate, in a population of chronic neuromuscular disease the non-inferiority of a rehabilitation treatment integrated with robotic and\u002For technological devices compared to traditional rehabilitation treatment in the level of fatigue.\n\nThe main question it aims to answer is:\n\nAre high-tech rehabilitation interventions, including robotic systems, virtual reality, and stabilometric platforms, not inferior to traditional rehabilitation methods in improving balance, motor function, fatigue levels, sarcopenia, cognitive engagement, and overall quality of life in patients with chronic neuromuscular diseases (NMDs)? Researchers will compare a robotic treatment group, that consists in an high-tech rehabilitation, with a control group, that will receive the traditional rehabilitative treatment.",[179,180,146],"Amyotrophic Lateral Sclerosis","Chronic Inflammatory Demyelinating Neuropathy",[182,183,184],"high-tech rehabilitation","chronic neuromuscular disease","robotic platform","2025-06-10",{"date":187,"type":42},"2025-06-11",{"date":189,"type":42},"2025-04-28",{"date":191,"type":21},"2026-03",{"name":193,"class":49},"Istituti Clinici Scientifici Maugeri SpA",7,{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":59,"sex":17,"minAge":201,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":80},"100531691","charcot-marie-tooth-disease-cmt-biological-sample-collection-for-ipsc-generation-and-biobanking-100531691","NCT06203093","Charcot-Marie-Tooth Disease (CMT) Biological Sample Collection for IPSC Generation and Biobanking","Inclusion Criteria:\n\n* Age 5 years or older.\n* Diagnosis of Charcot-Marie-Tooth (CMT) disease or healthy controls.\n* Adults must provide written informed consent unless physical limitations preclude signing.\n* Minors undergoing skin collection for research purposes must have a CMT diagnosis and must participate with parent\u002Fguardian consent.\n* Minors undergoing blood and\u002For saliva collection for research purposes or who transfer biological samples from a procedure outside the research may have a CMT diagnosis or serve as a healthy control and may participate with parent\u002Fguardian consent.\n\nExclusion Criteria:\n\n* Wards of the state.\n* For prospective skin samples: history of keloid formation, coagulation disorder, allergy to the anesthetic, or anticoagulation use that precludes sample collection.\n* For prospective blood samples: coagulation disorder or other medical conditions that increase the risks associated with blood collection.\n* For all prospective sample collections: Subjects who refuse to adhere to NYSCF's and\u002For a collaborating site's safety protocols will be excluded. Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter of blood will be excluded due to increased risk of infection.","5 Years",{"count":143,"type":21},"The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate Charcot-Marie-Tooth disease research and drug development by using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and\u002For store the samples for future use.\n\nThrough this research, researchers hope to identify future treatments or even cures for Charcot-Marie-Tooth disease.",[146,205],"Healthy",[31],"2025-02-27",{"date":209,"type":42},"2025-03-03",{"date":211,"type":42},"2022-09-22",{"date":213,"type":21},"2025-09-22",{"name":215,"class":49},"New York Stem Cell Foundation Research Institute",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":225,"conditions":226,"keywords":273,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":80},"100508586","natural-history-study-for-charcot-marie-tooth-disease-100508586","NCT05902351","Natural History Study for Charcot Marie Tooth Disease","Global Registry for Inherited Neuropathies Natural History Study for Charcot Marie Tooth Disease","Inclusion Criteria:\n\nPatients will be made aware of the study by HNF and others (referenced above) and invited to participate. Once patients have reviewed and signed electronically the informed consent document, it is attached to their file.\n\nAll affected individuals with CMT\u002FIN are eligible to participate in GRIN with proper informed consent.\n\nChildren, adolescents and adults with either a confirmed diagnosis or suspected to have CMT\u002FIN are eligible with parent and\u002For guardian consent.\n\nIndividuals that have been clinically diagnosed through family history and\u002For standard clinical testing (e.g. neuro exam, EMG, NCS) and\u002For genetically tested or suspected to have CMT\u002FIN (note: many mutations have not been identified yet) are eligible.\n\nExclusion Criteria:\n\nPeople that do not have Charcot-Marie-Tooth or other Inherited Neuropathies",{"count":224,"type":21},10000,"The goal of this Natural History Study for Charcot-Marie-Tooth is to acquire, record, and analyze patient-reported data and associated genetic reports, Electronic Health Records (EHRs) and clinical notes to identify the burden, diagnostic journey, and prevalence of disease that will aid scientists in their work toward finding a cure.\n\nParticipants will be asked to complete a Natural History Survey.",[146,31,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272],"Charcot-Marie-Tooth Disease, Type IA","Charcot-Marie-Tooth Disease Type 2A","Charcot-Marie-Tooth Disease Type 2","Charcot-Marie-Tooth Disease, Type 2C","Charcot-Marie-Tooth Disease Type 2A2B","Charcot-Marie-Tooth Disease Type 2B2","Charcot-Marie-Tooth Disease Type 2A1","Charcot-Marie-Tooth Disease Type 4B1","Charcot-Marie-Tooth Disease, Type IB","Charcot-Marie-Tooth Disease Type 2B1","Charcot-Marie-Tooth Disease Type 2U (Diagnosis)","Charcot-Marie-Tooth Disease Type 4A","Charcot-Marie-Tooth Disease, Type 4A, Axonal Form","Charcot-Marie-Tooth Disease Type 2A2A","Charcot-Marie-Tooth Disease Type 2S (Disorder)","Charcot-Marie-Tooth Disease and Deafness","Charcot-Marie-Tooth Disease Type 4B2","Charcot-Marie-Tooth Disease Type 4H","Charcot-Marie-Tooth Disease Type 1F","Charcot-Marie-Tooth Disease Type 4C","Charcot-Marie-Tooth Disease Type 4E","Charcot-Marie-Tooth Disease Type 1D","Charcot-Marie-Tooth Disease Type 2Q (Diagnosis)","Charcot-Marie-Tooth Disease Type 2A2","Charcot-Marie-Tooth Disease Type 2N (Diagnosis)","Charcot-Marie-Tooth Disease Type 2B5","Charcot-Marie-Tooth Disease Type 2D","Charcot-Marie-Tooth Disease Type 4D","Charcot-Marie-Tooth Disease Type 2K","Charcot-Marie-Tooth Disease Type 2L (Diagnosis)","Charcot-Marie-Tooth Disease Type 2T","Charcot-Marie-Tooth Disease Type 2I","Charcot-Marie-Tooth Disease Type 2J","Charcot-Marie-Tooth Disease Type 2E","Charcot-Marie-Tooth Disease Type 2G","Charcot-Marie-Tooth Disease Type 1C","Charcot-Marie-Tooth Disease Type 2R","Charcot-Marie-Tooth Disease Type 2O (Diagnosis)","Charcot-Marie-Tooth Disease Type 2M","Charcot-Marie-Tooth Disease Type 2P","Charcot-Marie-Tooth Disease Type 2Y","Charcot-Marie-Tooth Disease Type 4F (Diagnosis)","Charcot-Marie-Tooth Disease Type 4B3","Charcot-Marie-Tooth Disease Type 2H","HNPP","X-Linked Charcot-Marie-Tooth Disease",[274,147,31,146,66],"Inherited Neuropathies","2024-09-30",{"date":277,"type":42},"2024-10-01",{"date":279,"type":42},"2013-11-01",{"date":281,"type":21},"2029-12-31",{"name":283,"class":284},"Hereditary Neuropathy Foundation","OTHER_GOV",{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":59,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":292,"targetDuration":294,"studyType":22,"phases":4,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":80},"100363282","a-registered-cohort-study-on-charcot-marie-tooth-disease-100363282","NCT04010188","A Registered Cohort Study on Charcot-Marie-Tooth Disease","A Registered Observational Cohort Study of Charcot-Marie-Tooth Disease","Inclusion Criteria:\n\n* Patients with the clinical diagnosis of Charcot-Marie-Tooth disease\n* Genetic diagnosis of patients with Charcot-Marie-Tooth disease\n* Unrelated healthy controls\n\nExclusion Criteria:\n\n* Decline to participate.\n* Other peripheral neuropathy caused by trauma, immunity and toxicosis.",{"count":293,"type":21},500,"20 Years","The aim of the study is to analyze the natural history data data from Charcot-Marie-Tooth disease and related disorders in China, to assess the clinical, genetic, epigenetic features of patients with Charcot-Marie-Tooth disease, and to optimize clinical management.",[146],"2022-01-07",{"date":299,"type":42},"2022-01-11",{"date":301,"type":42},"2019-07-01",{"date":303,"type":21},"2049-12-31",{"name":305,"class":49},"Ning Wang, MD., PhD."]